- Home
- ZBAI vs COCP Comparison
ZBAI vs COCP Comparison
Compare ZBAI & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- COCP
- Stock Information
- Founded
- ZBAI 2015
- COCP 2006
- Country
- ZBAI United States
- COCP United States
- Employees
- ZBAI N/A
- COCP N/A
- Industry
- ZBAI Professional Services
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- COCP Health Care
- Exchange
- ZBAI Nasdaq
- COCP Nasdaq
- Market Cap
- ZBAI 17.3M
- COCP 15.7M
- IPO Year
- ZBAI N/A
- COCP N/A
- Fundamental
- Price
- ZBAI $0.49
- COCP $1.63
- Analyst Decision
- ZBAI
- COCP Strong Buy
- Analyst Count
- ZBAI 0
- COCP 1
- Target Price
- ZBAI N/A
- COCP $7.00
- AVG Volume (30 Days)
- ZBAI 962.4K
- COCP 27.4K
- Earning Date
- ZBAI 03-13-2025
- COCP 05-15-2025
- Dividend Yield
- ZBAI N/A
- COCP N/A
- EPS Growth
- ZBAI N/A
- COCP N/A
- EPS
- ZBAI N/A
- COCP N/A
- Revenue
- ZBAI $670,000.00
- COCP N/A
- Revenue This Year
- ZBAI N/A
- COCP N/A
- Revenue Next Year
- ZBAI N/A
- COCP N/A
- P/E Ratio
- ZBAI N/A
- COCP N/A
- Revenue Growth
- ZBAI 67.50
- COCP N/A
- 52 Week Low
- ZBAI $0.47
- COCP $1.12
- 52 Week High
- ZBAI $2.50
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- ZBAI N/A
- COCP 56.83
- Support Level
- ZBAI N/A
- COCP $1.55
- Resistance Level
- ZBAI N/A
- COCP $1.81
- Average True Range (ATR)
- ZBAI 0.00
- COCP 0.15
- MACD
- ZBAI 0.00
- COCP 0.02
- Stochastic Oscillator
- ZBAI 0.00
- COCP 56.10
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).